H.R. 3, Lower Drug Costs Now Act of 2019

Amdt/Mtn

Offered By

Description

Action

Roll Call

H.R. 3

#1

Mr. Scott

Amendment in the Nature of a Substitute

adopted by voice vote

#2

Mr. Walberg/ Ms. Stefanik

Excludes Alzheimer’s drugs from negotiation-eligible drugs

defeated 19-26

1

#3

Mr. Norcross

Clarifies that out of pocket costs cannot exceed the negotiated price

adopted by voice vote

#4

Mr. Allen

Requires the Secretary of Labor to certify that the voluntary plan option will not result in a shift in biotech investment and manufacturing jobs to China

defeated 20-26

2

#5

Mrs. Trahan

Requires GAO to conduct a study on the implementation of the Fair Price Negotiation Program

adopted by voice vote

#6

Mr. Johnson

States that the bill does not implicate fiduciary liability with regard to the negotiation program

defeated 20-26

3

#7

Ms. Jayapal

Requires the Department of Labor to conduct a feasibility study regarding establishing an inflation rebate for group health plans

adopted by voice vote

#8

Mrs. Foxx

Amends employer reporting to only require report if selected drug prices are higher than HHS price

defeated 21-26

4

#9

Mr. Harder/   Mr. Trone

Clarifies that the Secretary must ensure that data collection under the bill is coordinated with, and not duplicative of, other data collection efforts

adopted by voice vote

#10

Mrs. Foxx

Prevents the bill from going into effect if GAO finds it will result in the loss of manufacturing jobs

defeated 21-26

5

#11

Mr. Walker

Prevents the bill from going into effect if GAO finds it will result in decreased research and development

defeated 21-27

6

#12

Mr. Roe

ruled non-germane

#13

Mr. Roe

Prevents the voluntary plan option from taking effect unless the Secretary or Labor certifies it will not result in diminished access to drugs in group health plans

defeated 21-27

7

Motion

Ms. Shalala

Report H.R. 3

adopted 27-21

8